stoxline Quote Chart Rank Option Currency Glossary
  
OnKure Therapeutics, Inc. (OKUR)
5.45  0 (0%)    02-12 16:00
Open: 5.5
High: 5.55
Volume: 35,064
  
Pre. Close: 5.45
Low: 5.305
Market Cap: 69(M)
Technical analysis
2025-02-12 4:47:00 PM
Short term     
Mid term     
Targets 6-month :  8.61 1-year :  10.64
Resists First :  7.37 Second :  9.1
Pivot price 5.62
Supports First :  4.57 Second :  3.8
MAs MA(5) :  5.65 MA(20) :  5.71
MA(100) :  12.68 MA(250) :  14.67
MACD MACD :  -0.8 Signal :  -1
%K %D K(14,3) :  52.4 D(3) :  57.8
RSI RSI(14): 34.3
52-week High :  19.99 Low :  4.57
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ OKUR ] has closed above bottom band by 35.9%. Bollinger Bands are 67.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 5.56 - 5.59 5.59 - 5.62
Low: 5.22 - 5.26 5.26 - 5.3
Close: 5.39 - 5.45 5.45 - 5.5
Company Description

OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.

Headline News

Tue, 11 Feb 2025
FY2025 Earnings Estimate for OKUR Issued By Leerink Partnrs - Defense World

Thu, 23 Jan 2025
OnKure Therapeutics (NASDAQ:OKUR) Trading Down 3.4% – Here’s Why - Defense World

Tue, 10 Dec 2024
OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219 - GlobeNewswire

Thu, 05 Dec 2024
OnKure Therapeutics stock has strong potential with Outperform rating from Leerink - Investing.com

Fri, 01 Nov 2024
OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium - GlobeNewswire

Fri, 04 Oct 2024
OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million - StockTitan

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Neutral
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 13 (M)
Shares Float 4 (M)
Held by Insiders 1.4 (%)
Held by Institutions 55.2 (%)
Shares Short 1,410 (K)
Shares Short P.Month 1,240 (K)
Stock Financials
EPS 0.07
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -10.08
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) 0 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -3.57
Qtrly Earnings Growth 0 %
Operating Cash Flow -35 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio 68.12
PEG Ratio 0
Price to Book value -0.55
Price to Sales 0
Price to Cash Flow -1.99
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android